HRP20020286A2 - Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog - Google Patents

Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog Download PDF

Info

Publication number
HRP20020286A2
HRP20020286A2 HR20020286A HRP20020286A HRP20020286A2 HR P20020286 A2 HRP20020286 A2 HR P20020286A2 HR 20020286 A HR20020286 A HR 20020286A HR P20020286 A HRP20020286 A HR P20020286A HR P20020286 A2 HRP20020286 A2 HR P20020286A2
Authority
HR
Croatia
Prior art keywords
receptor antagonist
phenyl
methyl
ethyl
ethylcarbamoyl
Prior art date
Application number
HR20020286A
Other languages
English (en)
Croatian (hr)
Inventor
John Hughes
Singh Lakhbir
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP20020286A2 publication Critical patent/HRP20020286A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20020286A 1999-10-07 2000-10-05 Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog HRP20020286A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
HRP20020286A2 true HRP20020286A2 (en) 2003-08-31

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020286A HRP20020286A2 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (de)
JP (2) JP2003510356A (de)
KR (1) KR20020060192A (de)
CN (1) CN1387434A (de)
AP (1) AP2002002501A0 (de)
AR (1) AR029646A1 (de)
AT (1) ATE269072T1 (de)
AU (2) AU7663300A (de)
BG (1) BG106548A (de)
BR (1) BR0014598A (de)
CA (1) CA2385930A1 (de)
CO (1) CO5280195A1 (de)
CR (1) CR6614A (de)
CZ (1) CZ20021116A3 (de)
DE (1) DE60011650T2 (de)
DK (1) DK1221950T3 (de)
EA (1) EA004266B1 (de)
EE (1) EE200200185A (de)
ES (1) ES2220542T3 (de)
GT (1) GT200000166A (de)
HR (1) HRP20020286A2 (de)
HU (1) HUP0203466A3 (de)
IL (1) IL148965A0 (de)
IS (1) IS6318A (de)
MA (1) MA26826A1 (de)
MX (1) MXPA02003484A (de)
NO (1) NO20021625D0 (de)
NZ (1) NZ517949A (de)
OA (1) OA12063A (de)
PA (1) PA8504301A1 (de)
PE (1) PE20010708A1 (de)
PL (1) PL357498A1 (de)
PT (1) PT1221950E (de)
SK (1) SK4542002A3 (de)
TR (1) TR200200913T2 (de)
UY (1) UY26376A1 (de)
WO (2) WO2001024792A1 (de)
ZA (1) ZA200202675B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (de) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba und dessen derivate zur schmerzbehandlung
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
FI3946260T3 (fi) * 2019-03-26 2026-03-24 Orion Corp Pregabaliiniformulaatioita ja niiden käyttö
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
BR0014598A (pt) 2002-06-11
PT1221950E (pt) 2004-08-31
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
ZA200202675B (en) 2003-04-15
EP1221950B1 (de) 2004-06-16
WO2001024791A1 (en) 2001-04-12
ATE269072T1 (de) 2004-07-15
AP2002002501A0 (en) 2002-06-30
BG106548A (en) 2002-12-29
UY26376A1 (es) 2000-12-29
IL148965A0 (en) 2002-11-10
WO2001024792A9 (en) 2002-09-06
AU7663300A (en) 2001-05-10
SK4542002A3 (en) 2003-09-11
TR200200913T2 (tr) 2002-09-23
KR20020060192A (ko) 2002-07-16
JP2003510355A (ja) 2003-03-18
CO5280195A1 (es) 2003-05-30
DK1221950T3 (da) 2004-09-20
PL357498A1 (en) 2004-07-26
OA12063A (en) 2006-05-03
NO20021625L (no) 2002-04-05
HUP0203466A3 (en) 2005-03-29
HUP0203466A2 (hu) 2003-02-28
NO20021625D0 (no) 2002-04-05
PE20010708A1 (es) 2001-07-27
GT200000166A (es) 2002-03-30
ES2220542T3 (es) 2004-12-16
AU1696201A (en) 2001-05-10
MXPA02003484A (es) 2004-09-10
CA2385930A1 (en) 2001-04-12
CN1387434A (zh) 2002-12-25
EP1233766A1 (de) 2002-08-28
IS6318A (is) 2002-03-21
EA004266B1 (ru) 2004-02-26
NZ517949A (en) 2003-08-29
EA200200303A1 (ru) 2002-08-29
CZ20021116A3 (cs) 2003-05-14
DE60011650D1 (de) 2004-07-22
MA26826A1 (fr) 2004-12-20
EE200200185A (et) 2003-04-15
WO2001024792A1 (en) 2001-04-12
AR029646A1 (es) 2003-07-10
EP1221950A1 (de) 2002-07-17
DE60011650T2 (de) 2005-07-14
CR6614A (es) 2003-12-04

Similar Documents

Publication Publication Date Title
KR100537707B1 (ko) 항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법
US20120101121A1 (en) drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-b) indoles, its pharmacological compound and application method
JP2000507544A (ja) 痛みの治療方法
NZ518901A (en) A levetiracetam alone or in combination with a compound inducing neural inhibition mediated by the GABA receptors for treatment of chronic pain, bipolar disorder, mania and migraine
EP1058559B1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
Klamt et al. Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia
EP1221950B1 (de) Synergistische kombination von nk1-rezeptor antagonisten und gaba analogen
Shaban et al. Evaluation of the antinociceptive effect of xylazine and it’s interaction with metoclopramide in the acute pain model in mice
CN106456637B (zh) (s)-吡吲哚及其药学上可接受的盐的药学用途
US20020016319A1 (en) Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
US6680343B1 (en) Treatment of renal colic with GABA analogs
CA2609972A1 (en) Method and compositions for treatment of chronic neuropathic pain
Konkle et al. Feeding and reward interactions from chronic paroxetine treatment
US20220273596A1 (en) Synergistic combination of s-ketorolac and pregabalin in a pharmaceutical composition for the treatment of neuropathic pain
EP0901376A1 (de) Melatonin in kombination mit analgetika
Alvarez et al. Antihyperalgesic effects of clomipramine and tramadol in a model of posttraumatic trigeminal neuropathic pain in mice.
Göbel et al. Treatment of Pain Due to Postherpetic Neuralgia with Tramadol: Results of an Open, Parallel Pilot Study vs Clomipramine With or Without Levomepromazine
US20060089412A1 (en) Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease
EP1656933A1 (de) Medizinische Zusammensetzung enthaltend L-Alanin zur Behandlung von nichtalkoholischer Fettlebererkrankung und/oder nichtalkoholischer Steatohepatitis
ZA200007172B (en) The treatment of renal colic with GABA analogs.
JP2005154368A (ja) ジソピラミド含有神経因性疼痛の鎮痛剤

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn